OCT 11, 2017 7:30 AM PDT

Keynote Presentation: Targeting Molecular Chaperones in Cancer: Lessons Learned from HSP90

Speaker

Abstract

The first small molecule inhibitor of the molecular chaperone Heat Shock Protein 90 (HSP90) was identified more than 20 years ago. Upon determination of the drug binding site and clarification of its mechanism of action, HSP90 was validated as an anti-cancer molecular target, robust preclinical activity was demonstrated, and the first clinical trials of an HSP90 inhibitor in cancer patients were initiated several years later. Since then, additional natural product and synthetic HSP90 inhibitors have been identified and many have been clinically evaluated. As a class, these inhibitors are ATP-competitive and inhibit the ATPase driven HSP90 chaperone cycle, causing degradation of HSP90-dependent proteins (termed clients), including many oncogenes, via the proteasome. While numerous clinical trials have been performed with HSP90 inhibitors and encouraging data have been obtained, no HSP90 inhibitor has yet received FDA approval. One consequence of HSP90 inhibition is upregulation of the cytoprotective heat shock response, a broad transcriptional response to proteotoxic stress that is regulated by the transcription factor Heat Shock Factor 1 (HSF1). HSF1 also mediates a cancer-specific transcriptional program. HSP90 is proposed to sequester HSF1 in unstressed cells, but there is little evidence to support this model. A better mechanistic understanding of the role of HSP90 in modulating HSF1 may facilitate improved clinical activity of HSP90 inhibitors. We recently showed that HSP90 binding to HSF1 depends on HSP90 conformation and is only readily visualized for the ATP-dependent, N-domain dimerized chaperone, a conformation only rarely sampled by mammalian HSP90. Further, we show that ATP-competitive, N-domain targeted HSP90 inhibitors disrupt this interaction, resulting in the increased duration of HSF1 occupancy of the hsp70 promoter and significant prolongation of both constitutive and heat-induced HSF1 transcriptional activity. Not only do these suggest a role for HSP90 in feedback regulation of the proteotoxic stress response, but this characteristic of current HSP90 inhibitors likely contributes to lack of robust clinical response and we are currently evaluating several strategies that target HSP90 inhibitor effects on HSF1 without impacting HSP90 inhibitor-mediated degradation of oncogenic clients. Finally, a consistent property of HSP90 inhibitors to concentrate in tumors and to remain for an extended time period compared to normal tissues has prompted the use of HSP90 inhibitors as intracellular delivery vehicles to direct and concentrate conjugated cytotoxic agents in tumor while sparing normal tissues. This strategy extends the potential clinical utility of HSP90 inhibitors in cancer and a Phase 1 trial of such an HSP90-drug conjugate is underway.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
AUG 16, 2022 11:00 AM PDT
AUG 16, 2022 11:00 AM PDT
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
JUL 26, 2022 9:00 AM PDT
JUL 26, 2022 9:00 AM PDT
Date: July 26, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Organoids and spheroids are increasingly being used in many research applications, including drug discovery, toxicology,...
OCT 11, 2017 7:30 AM PDT

Keynote Presentation: Targeting Molecular Chaperones in Cancer: Lessons Learned from HSP90



Show Resources
Loading Comments...
Show Resources